Genedata Biologics Usage Expanded by Sanofi for Platformization of HT Multi-Specific Antibody Engineering

Global Biopharma leader drives digital innovation and AI-based biopharma R&D by expanding footprint of Genedata Biopharma Platform

October 6, 2022
Basel, Switzerland

Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced that Sanofi has expanded the use of Genedata Biologics^® to new sites, groups, and application areas, including high-throughput engineering of next-generation multi-specific antibody therapeutics. 

“We chose Genedata Biologics to support our quickly growing biopharmaceutical R&D operations and enable scientific innovation, including R&D of novel modalities such as bi- and multi-specifics and other next-gen therapeutics,” said Rebecca Sendak, Ph.D., Senior Vice President of Global Large Molecules Research Platform at Sanofi.

Genedata Biologics is used by major biopharma R&D organizations as a backbone for integrating globally operating research groups. Due to its flexible and scalable architecture, it facilitates the onboarding and integration of new R&D groups.

A key driver for extending the use of Genedata Biologics was the ability of the platform to implement fully automated end-to-end processes for generating rich data packages around innovative multi-specific antibody therapeutics. In addition to acting as an automation platform, Genedata Biologics provides a foundation of structured and accessible data that can feed into AI/ML workflows.

The Genedata Biologics foundation is complemented with other Sanofi enterprise systems and together they contribute to optimizing overall R&D operations by:
a)    enabling users to monitor program performance, resource and project planning, and task prioritization.
b)    providing a means for scientists, managers, and executives to have real-time access to data, which is the basis for systematic and transparent decisions on the biotherapeutic candidates to be progressed to the clinic. 

“We are pleased that our long-term partner Sanofi continues to expand their usage of Genedata Biologics,” said Othmar Pfannes, Ph.D., CEO of Genedata. “The digital transformation of biopharmaceutical R&D is continuing at a rapid pace as companies strive to better organize and analyze their R&D data. We are excited that our technology is helping Sanofi and our other partners to develop innovative biotherapies faster.” 

More details on the use of Genedata Biologics at Sanofi can be found in the mAbs Journal (Furtmann et al., An end-to-end automated platform process for high-throughput engineering of next-generation multi-specific antibody therapeutics) or at www.tandfonline.com/doi/full/10.1080/19420862.2021.1955433.